|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2006-9-8
|
|
pubmed:abstractText |
GH deficiency is common in childhood cancer survivors. In a previous report, although we did not find an increase in the risk of disease recurrence in survivors treated with GH, GH-treated survivors did have an increased risk of developing a second neoplasm (SN) (rate ratio, 3.21).
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0021-972X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
91
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3494-8
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:16822820-Adolescent,
pubmed-meshheading:16822820-Adult,
pubmed-meshheading:16822820-Child,
pubmed-meshheading:16822820-Child, Preschool,
pubmed-meshheading:16822820-Cohort Studies,
pubmed-meshheading:16822820-Female,
pubmed-meshheading:16822820-Follow-Up Studies,
pubmed-meshheading:16822820-Human Growth Hormone,
pubmed-meshheading:16822820-Humans,
pubmed-meshheading:16822820-Male,
pubmed-meshheading:16822820-Neoplasms, Second Primary,
pubmed-meshheading:16822820-Proportional Hazards Models,
pubmed-meshheading:16822820-Questionnaires,
pubmed-meshheading:16822820-Retrospective Studies,
pubmed-meshheading:16822820-Risk Assessment
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor.
|
|
pubmed:affiliation |
Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York, 10021, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Research Support, N.I.H., Extramural
|
